Skip Navigation
 
 
 
 
 
Print This Page
Share this page: More
 

Van Eyk Lab

The Van Eyk research lab studies the underlying molecular mechanism of heart disease.

We use a wide variety of proteomic strategies that allow us to screen and characterize protein changes within the large number of subproteomes that comprise the cell. Animal models and human tissue or serum samples from acute and chronic heart disease are analyzed using large number of different protein/peptide separation methods coupled to mass spectrometry.

The goal is to identify the proteins and their isoform or post translational modifications that collectively produce the dysfunction that characterizes the disease phenotype. Coupling the detailed proteomic analysis with bioinformatics, cellular modeling and functional analysis allows us to piece together the complexity and the dynamics of the system. On the practical side, this information can provide leads for the development of therapeutics as well as identify potential biomarkers for the diagnosis, prognosis and risk stratification of heart disease.

Contact Information:  

Dr. Jennifer E. Van Eyk
jvaneyk1@jhmi.edu
410-550-8510 
Fax: 410-550-8511
     

Laboratory Location:  

602 Mason F. Lord Bldg., Center Tower,
JHU Bayview Campus
     

Research Focus:

Proteomic analysis of heart disease: from molecular mechanism to biomarker development
Our laboratory undertakes the study of the protein complement, or proteome, of cells, tissues or body fluids to understand the complex regulation and control that change with disease. This allows us to discover novel changes to the proteome that underpin the molecular mechanisms that drive disease. Furthermore, discovery of new potential biomarkers that are altered in plasma during disease onset and development allows us to create new diagnostics and prognostic tests for clinical use.

Funding Support:

Major funding sources

10/01/02 - 9/30/2009
Title: Proteomics of Adaptation to Ischemia/Hypoxia in Heart, Lung and Blood, IH N01-HV-28180, Funding agency: NIH/NHLBI

Contract 8/1/2004-6/30/2009
Title: Pathobiology of Cardiac Dyssynchrony and Resynchronization P01 HL77180-01 Funding agency: NIH/NHLBI

PPG 4/1/2005-3/31/2010
Title: Mitochondrial Function in Ischemic Heart Disease P01-HL081427-02 Funding agency: NIH/NHLBI

PPG 01/01/07 - 12/31/12
Title: Pulmonary Vascular Disease: translational to clinic P50 HL 084946-01 Funding agency: NIH/NHLBI
SCCOR

Industry Partnerships with
Unpath Inc
Varian Ludesi Inc.
Beckman Coulter
Applied Biosystems Inc

Active Projects:  

1. Biomarker development in the areas of myocardial ischemia, aortic dissection, sudden death and heart failure
2. Stem cell and cardiac progenitors cells in the areas of cell surface markers and the mechanism underlying control of differentiation.
3. Heart failure in the areas of phosphorylation in mitochondrial and myofilament regulation and membrane protein cell localization.
4. Myocardial ischemia and preconditioning in the areas of phosphorylation in mitochondrial regulation.
     

Laboratory Collaborators:

Examples of Collaborations within JHU Cardiology and Pediatrics
Gordon Tomaselli, MD
David Kass, MD

Brian O'Rourke, MD
Eduardo Marban, MD
Joao Lima, MD
Hal Dietz, MD
Anne Murphy, MD
Allen Everett, MD

Selected Bibliography:

Books Edited
Van Eyk JE, Dunn M, editors. Genomic and Proteomic Analysis of Cardiovascular Disease: molecular mechanism, therapeutic targets and diagnostics. Wiley and Son Inc., January 2003

Van Eyk JE, Dunn M., editors. Clinical Proteomics: from diagnosis to therapy. Wiley and Son Inc., Spring 2007

Reviews and Book Chapters
Stanley BA, Van Eyk JE. Clinical Proteomics - Technologies to define and diagnose heart disease in Molecular Mechanisms of Cardiac Hypertrophy and Failure (ed Walsh R) 2005 pp 651-666.

Jaffe AS, Van Eyk JE. Troponin Fragments-Diagnostic potential in Cardiac Biomarkers in the management of cardiac disease. (ed. Morrow DA) Contemporary Cardiology series. 2006 pp 161-176.

Fu Q, Van Eyk JE, Proteomics and heart disease: Identifying biomarkers of clinical utility. Expert Rev. Proteomics 2006;3:237-49

Manuscripts (selected from over 100)
66. Arrell DK, Elliott ST, Kane LA, Guo Y, Ko YH, Pedersen PL, Robinson J, Murata M, Murphy AM, Marban E, Van Eyk JE. Proteomic Analysis of Pharmacological Preconditioning. Novel Protein Targets Converge to Mitochondrial Metabolism Pathways. Circ Res. 2006;99:5:706-14.

Ji Y, Neverova I, Van Eyk JE, Bennett BM. Nitration of tyrosine 92 mediates the activation of rat microsomal glutathione s-transferase by peroxynitrite. J Biol Chem. 2006;281:1986-91

McDonald T, Sheng S, Stanley F, Chen D, Ko Y, Cole RN, Pederson P, Van Eyk JE. Expanding the subproteome of the inner mitochondria using protein separation technologies: one and two-dimensional liquid chromatography and two-dimensional gel electrophoresis. Mol. Cell. Proteomics 2006;5:2392-411.

Gundry RL, Fu Q, Jelinek CA, Van Eyk JE, Cotter RJ. Investigation of an albumin-enriched fraction of human serum and its albuminone. Proteomics: clinical applications 2007 (in press)

 
 

Make a Gift

Trainings and Fellowships

 

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

U.S. 1-410-464-6713 (toll free)
International +1-410-614-6424

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.